Market Overview

According to fortune business insights, The global hemato oncology testing market size was valued at USD 4.54 billion in 2025. The market is projected to grow from USD 4.84 billion in 2026 to USD 8.45 billion by 2034, exhibiting a CAGR of 7.2% during the forecast period. North America dominated the global hemato oncology testing market with a market share of 40.96% in 2025.

The analysis shows that market growth is attributed to the rising adoption of advanced tests for the detection of blood cancers such as leukemia, lymphoma, and myeloma. The introduction of easier-to-run tests, the rising prevalence of blood disorders, and a growing emphasis on preventive care are also driving market growth. Key industry players are focusing on introducing technologically advanced products to meet this demand.

Major Players Profiled in the Market Report:

• Hoffmann-La Roche AG (Switzerland)
• Abbott (U.S.)
• Danaher Corporation (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Agilent Technologies, Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Sysmex Corporation (Japan)
• Illumina, Inc. (U.S.)
• QIAGEN N.V. (Netherlands)
• BD (U.S.)
• Invivoscribe, Inc. (U.S.)
• Invitae Corporation (U.S.)

Segments

Significant Adoption of Assay Reagents and Kits to Accelerate Segmental Growth

Based on products & services, the market is divided into assay kits & reagents, services, and instruments & platforms. The assay kits & reagents segment holds the largest share due to repetitive purchases driven by high test volumes and growing awareness.

Higher Prevalence to Drive Lymphoma Segment Growth